Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma

  • Alexander MM Eggermont
  • , Andrey Meshcheryakov
  • , Victoria Atkinson
  • , Christian U. Blank
  • , Mario Mandala
  • , Georgina V. Long
  • , Catherine Barrow
  • , Anna Maria Di Giacomo
  • , Rosalie Fisher
  • , Shahneen Sandhu
  • , Ragini Kudchadkar
  • , Pablo Luis Ortiz Romero
  • , Inge Marie Svane
  • , James Larkin
  • , Susana Puig
  • , Peter Hersey
  • , Pietro Quaglino
  • , Paola Queirolo
  • , Daniil Stroyakovskiy
  • , Lars Bastholt
    • Peter Mohr, Micaela Hernberg, Vanna Chiarion-Sileni, Matthew Strother, Axel Hauschild, Naoya Yamazaki, Alexander CJ van Akkooi, Paul Lorigan, Clemens Krepler, Nageatte Ibrahim, Sandrine Marreaud, Michal Kicinski, Stefan Suciu, Caroline Robert

Research output: Contribution to journal › Article › peer-review

23 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Neuroscience